Conventional CPAP Airsense 10 VS Portable Air-Mini CPAP For Obstructive Sleep Apnea (CASPA
Obstructive sleep apnea (OSA) has been one of the topmost global health problems. It is an underdiagnosed disease which have a huge burden on healthcare if left untreated. Almost 80-90% of adults are underdiagnosed of OSA Obesity primarily is one of the supreme risk factors for developing OSA. Globally, obesity cases h
| Condition(s) | Obstructive Sleep Apnea |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Obstructive sleep apnea (OSA) has been one of the topmost global health problems. It is an underdiagnosed disease which have a huge burden on healthcare if left untreated. Almost 80-90% of adults are underdiagnosed of OSA Obesity primarily is one of the supreme risk factors for developing OSA. Globally, obesity cases have risen affecting almost two billion people. According to National Health and Morbidity Survey (NHMS) 2019, 1 in 2 adults in Malaysia were overweight or obese. Report from World Obesity Atlas 2023 predicts that adult obesity will rise 4.7% annually from 2020 - 2035, while child obesity will increase by 5.3% per year over similar timeline. Overweight individuals will have a significant economic impact on Malaysia's Gross Domestic Product (GDP) by 2035 by 2.8% which is estima |
| Who can participate | Inclusion Criteria: * Aged ≥ 18 years. * Patients diagnosed with moderate to severe OSA (based on AHI classification from sleep study performed). * Patients who are able to understand and answer the questionnaire given. Exclusion Criteria: * Patients who are unable to give consent to the study. * Patients who have been diagnosed with OSA and already on CPAP machine. * Patients who had underlying Obesity Hypoventilation Syndrome (OHS). * Patients who had underlying co-morbidities that worsen apnea symptoms, such as congestive cardiac failure, active malignancy, narcolepsy, active alcohol or drug abuse, treatment-refractory dementia, psychotic illness and active use of drugs that disturb the sleep architecture (i.e hypnotics or stimulants of central nervous system). |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | National University of Malaysia |
| Locations | Cheras, Kuala Lumpur, Malaysia |
| Start date | 2024-09-01 |
| NCT ID | NCT06564896 |
| Official listing | https://clinicaltrials.gov/study/NCT06564896 |